OKOlayinka Adejoke Kotila

Olayinka Adejoke Kotila

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olayinka Adejoke Kotila has a total of 86 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Method Development and Validation of the HPLC Analysis of Dolutegravir in Bulk Form and Human Plasma

    by Olayinka Adejoke Kotila, Oluwaseyi David Akin-Ojo, Philip Chukwuemeka, Olufemi James Adegbola, Chinedum Peace Babalola

    Background/Objectives: Dolutegravir is an integrase strand transfer inhibitor widely used in HIV therapy due to its high resistance barrier and favourable safety profile. As pharmacopoeial coverage continues to evolve and local formulation efforts increase, relia-ble analytical methods are required to ensure drug quality, safety, and efficacy. This study aimed to develop and validate two simple, sensitive, and cost-effective high-performance liquid chromatography with UV detection (HPLC-UV) methods for quantifying dolute-gravir in bulk form and human plasma. Methods: Reverse-phase HPLC methods were developed and validated according to ICH Q2(R2) guidelines. Hydrochlorothiazide and carbamazepine were used as internal standards for bulk and plasma analysis, respective-ly. Chromatographic separation was achieved on C18 columns. Key validation parameters included linearity, accuracy, precision, limit of detection (LOD), limit of quantitation (LOQ), robustness, and system suitability. Plasma samples were prepared using liquid–liquid extraction with diethyl ether. Results: The bulk method showed excellent linearity over 0.5–100 µg/mL with an R2 of 0.9997, while the plasma method was linear over 0.8–10 µg/mL with an R2 of 0.9956. Accuracy ranged from 95.2% to 104.4% for bulk and showed acceptable recoveries for plasma samples. Precision was satisfactory with %RSD values below 6% across all methods. LOD and LOQ were 0.42 µg/mL and 1.26 µg/mL for bulk analysis, and 0.55 µg/ml and 1.68 µg/ml, for plasma analysis respectively. Robustness and system suitability tests confirmed method reliability. Conclusions: The developed HPLC-UV methods are simple, reproducible, and suitable for routine quality control of dolutegravir in pharmaceutical formulations and for its quantification in human plasma for pharmacokinetic applications.

  • Open Access

    Pragmatic Clinical Trial Assessing Response to Neoadjuvant Docetaxel and Trastuzumab in Nigerian Women With Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer (ARETTA)

    by Atara Ntekim, Abiodun Popoola, Anthonia Sowunmi, Olalekan Olasehinde, Ayodele Sanni, Abiola Ibraheem, Yonglan Zheng, Toshio F. Yoshimatsu, Gideon T. Dosunmu, Olasubomi Omoleye, et al.

    PURPOSE: Breast cancer is the leading cause of death in Nigerian women. Clinical trials are required to provide evidence for treatment. We aimed to generate efficacy data to support the shift in local practice of neoadjuvant therapy for breast cancer. METHODS: A one-stage, phase II feasibility, single-arm study design was used. Treatment-naïve patients with clinically nonmetastatic human epidermal growth factor receptor 2 (HER2)–positive breast cancer received four cycles of neoadjuvant docetaxel with subcutaneous trastuzumab (T + scH). Patients with complete clinical response underwent surgery. Patients with stable disease/partial response received three further cycles of 5-fluorouracil, epirubicin, and cyclophosphamide + scH before surgery. Responders completed 18 scH cycles. The primary end point was pathologic complete response (pCR). The secondary end points were toxicity and invasive disease-free survival. RESULTS: A total of 53 female patients age 18-70 years were enrolled. The median age of the 47 evaluable female patients was 50 years. pCR was achieved in 25 of 47 patients (53% [95% CI, 38.1 to 67.9]; P < .001). Forty-two percent of patients were estrogen receptor+ and 40% were progesterone receptor+ (95% CI, 20.3 to 66.5 and 21.5 to 69.2, respectively). All were HER2+, with 40% stage II and 60% stage III disease. Three patients (6.4%) experienced grade 3 myelosuppression, one (2.1%) experienced grade 3 diarrhea, two (4.3%) had a grade 4 adverse event, and two developed hepatitis while on the study medications. The reporting of disease-free and overall survival awaits future analysis. CONCLUSION: This phase II study showed that neoadjuvant chemotherapy with T + scH resulted in pCR of 53%, surpassing the planned cutoff for success of 40%. This is comparable with the rates and other efficacy end points that follow data from phase II international trials. This regimen may be useful in the absence of pertuzumab and warrants further investigation.


  • Open Access

    Identification of Antibiofilm Agents against Salmonella enterica from the Pathogen Box Compound Library

    by Adeshola A. Fagbemi, Chinedum P. Babalola, David A. Kwasi, Olabisi C Akinlabi, Olayinka Kotila, Iruka N. Okeke

    Background: Biofilms are central to Salmonella pathogenesis, and targeting their formation is believed to produce less evolutionary pressure of growth inhibition than traditional antibacterials. In this study, we screened the Medicines for Malaria Venture (MMV) Pathogen Box library to identify anti-biofilm agents against S . enterica that possess drug-like properties. Methodology/ Principal Findings: A crystal-violet-based medium-throughput antibiofilm screen of Salmonella enterica serovar Typhimurium ATCC 14028 and a clinical Salmonella enterica serovar Elisabethville isolate was performed on polystyrene surfaces using the 400-compound Pathogen Box library. Compounds that inhibited biofilm formation by >30% and growth by Salmonella red-dry-rough and motility phenotypes were explored in mechanism of action studies on one hit compound. The Salmonella antibiofilm hit rate was 0.75% for this library. MMV688371 (benzamide) inhibited biofilm formation of S . Typhimurium ATCC 14028 by 33% without inhibiting growth. An ethambutol analogue (MMV687273) and auranofin (MMV688978) met the hit criteria against S . Elisabethville LLD035X. Auranofin showed concentration-dependent, growth-inhibition-independent antibiofilm activity against typhoidal and non-typhoidal Salmonella from Nigeria, and inhibited the motility of S . Elisabethville LLD035X at 5 µM. At 5 µM aurothioglucose, an auranofin gold (I) analogue, and non-gold analogue 1-Thio-beta-D-glucose tetraacetate, inhibited biofilm formation by 61.30% and 11.39%, respectively, pointing to essentiality of the gold (I) moiety for activity. Conclusions/ Significance: Structurally diverse small molecules can inhibit biofilm formation by Salmonella, and motility inhibition is an important mechanism for this activity. Auranofin inhibits typhoidal and non-typhoidal Salmonella biofilm formation, with its gold content being required for these activities.

  • Open Access

    Challenges and Recommendations for Improving Cancer Research and Practice in Nigeria: A Qualitative Study With Multi-Stakeholders in Oncology Research and Practice

    by Mojisola M Oluwasanu, Prisca O Adejumo, Yijia Sun, Chidera Onwuka, Atara Ntekim, Olutosin A Awolude, Toyin I Aniagwu, Olayinka A Kotila, Biobele J Brown, Godwin I Ogbole, et al.

    Background: Cancers, with increasing incidence and mortality rates, constitute a leading public health problem in Nigeria. As the burden of cancer in Nigeria increases, research and quality service delivery remain critical strategies for improved cancer control across the continuum of care. This study contextualizes the challenges and gaps in oncology research and practice in Nigeria, and presents recommendations to address the gaps. Methods: This qualitative study was conducted among interprofessional and interdisciplinary stakeholders in oncology healthcare practice and research in academic settings, between July and September 2021. Key-informant interviews were held with six stakeholders and leaders in nursing, pharmacy, and medicine across the six geopolitical zones of Nigeria, and twenty-four in-depth interviews with early- or mid-career researchers or healthcare professionals involved in cancer prevention and treatment were conducted. The data were analyzed using a deductive thematic analysis approach and coded using the NVIVO 12 software. Results: Five sub-themes were identified as major challenges to oncology research, including poor funding, excessive workload, interprofessional rivalry, weak collaboration, and denial of cancer diagnosis by patients. Challenges identified for oncology practice were poor governance and financing, high costs of oncology treatments, poor public awareness of cancer, workforce shortage, and interprofessional conflicts. Recommended strategies for addressing these challenges were improved financing of oncology research and practice by government and relevant stakeholders, increasing interest of medical, nursing, and pharmaceutical students in oncology research through curricula-based approach and mentorship, increased oncology workforce, and improved intra- and inter-professional collaboration. Conclusion: These data highlight the challenges and barriers in oncology practice and research in Nigeria, and underscore the urgent need for increased investments in infrastructure to provide interdisciplinary and interprofessional research training for high-quality care. Only then can Nigeria effectively tackle the current and impending cancer burden in the country.


  • Non‐compartmental and population pharmacokinetic analysis of dapsone in healthy NIGERIANS: A pilot study

    by Olayinka A. Kotila, David T. Ajayi, Collen Masimirembwa, Roslyn Thelingwani, Abayomi Odetunde, Adeyinka G. Falusi, Chinedum P. Babalola

    Dapsone is employed for both non‐dermatological and dermatological indications but with non‐existent population pharmacokinetics (popPK) data in Nigerians. This study was therefore designed to develop a popPK model in Nigerians. Non‐compartmental analysis and nonlinear mixed effects modelling were utilized for data analysis. Eleven participants administered 50 mg dapsone tablet were included in the analysis. Derived pharmacokinetic parameters were: Cmax = 1.16 ± 0.32 μg/mL, Tmax = 3.77 ± 2.40 h, and t1/2z = 30.23 ± 11.76 h. PopPK model parameter estimates with inter‐individual variability were Tlag = 0.40 h (10.0%, fixed); ka = 1.78 h−1 (75.9%); V/F = 89.25 L (21.6%); and Cl/F = 1.32 Lh−1 (27.7%). Sex was significantly associated with Cl/F, and body weight with V/F. Best popPK model was one‐compartment with lag time, and first‐order absorption and elimination. Sex and body weight significantly influenced the clearance and distribution volume of dapsone respectively.


  • Open Access

    Oncology Training Needs Assessment Among Health Care Professionals in Nigeria

    by Prisca Olabisi Adejumo, Mojisola Morenike Oluwasanu, Atara Ntekim, Olutosin Alaba Awolude, Olayinka Adejoke Kotila, Toyin Aniagwu, Biobele Jotham Brown, Bonaventure Suiru Dzekem, Susan Duncan, Moyinoluwalogo Tito-Ilori, et al.

    PURPOSE: This study investigated the status of training and preparedness for oncology practice and research and degree of interprofessional collaboration among health care professionals in the six geopolitical regions of Nigeria. METHODS: A convergent parallel mixed methods design was used. Three hundred seventeen respondents completed a three-part, online questionnaire. Self-rated competencies in oncology research (26 items), oncology practice (16 items), and interprofessional collaboration (nine items) were assessed with a one- to five-point Likert scale. Six key informant and 24 in-depth interviews were conducted. Descriptive statistics, analysis of variance, and pairwise t-test were used to analyze the quantitative data, whereas thematic analysis was used for the qualitative data. RESULTS: Respondents were mostly female (65.6%) with a mean age of 40.5 ± 8.3 years. Respondents include 178 nurses (56.2%), 93 medical doctors (29.3%), and 46 pharmacists (14.5%). Self-assessed competencies in oncology practice differed significantly across the three groups of health care professionals ( F = 4.789, P = .009). However, there was no significant difference across professions for competency in oncology research ( F = 1.256, P = .286) and interprofessional collaboration ( F = 1.120, P = .327). The majority of respondents (267, 82.4%) felt that educational opportunities in oncology-associated research in the country are inadequate and that this has implications for practice. Key training gaps reported include poor preparedness in data analysis and bioinformatics (138, 43.5%), writing clinical trials (119, 37.5%), and writing grant/research proposals (105, 33.1%). Challenges contributing to gaps in cancer research include few trained oncology specialists, low funding for research, and inadequate interprofessional collaboration. CONCLUSION: This study highlights gaps in oncology training and practice and an urgent need for interventions to enhance interprofessional training to improve quality of cancer care in Nigeria. These would accelerate progress toward strengthening the health care system and reducing global disparities in cancer outcomes.


  • Open Access

    Causes and remedies for low research productivity among postgraduate scholars and early career researchers on non-communicable diseases in Nigeria

    by Mojisola Morenike Oluwasanu, Ntekim Atara, Williams Balogun, Olutosin Awolude, Olayinka Kotila, Toyin Aniagwu, Prisca Adejumo, Omobolanle Olaronke Oyedele, Millicent Ogun, Ganiyu Arinola, et al.

    The aim of the descriptive, cross sectional, questionnaire-based study reported here was to explore the causes of low productivity in non-communicable diseases research among postgraduate scholars and early career researchers in Nigeria and identify measures that could facilitate increased research output. The 89 respondents were masters-level, doctoral scholars and resident doctors who attended a workshop. Majorities of the respondents (over 70%) either agreed or strongly agreed that factors contributing to poor non-communicable diseases research productivity include a dearth of in-country researchers with specialized skills, inability of Nigerian researchers to work in multidisciplinary teams, poor funding for health research, sub-optimal infrastructural facilities, and limited use of research findings by policy makers. Almost all the respondents (over 90%) agreed that potential strategies to facilitate non-communicable diseases research output would include increased funding for research, institutionalization of a sustainable, structured capacity building program for early career researchers, establishment of Regional Centers for Research Excellence, and increased use of research evidence to guide government policy actions and programs.